Loading
Review of Case Materials
Reviews records, documents, testimony, data, and other relevant materials and consults with counsel regarding technical issues related to the matter.
Provide Expert Analysis
Applies specialized knowledge and experience to evaluate the technical or professional issues involved.
Form Expert Opinions
Develops independent, supportable opinions based on the available evidence and relevant standards.
Prepare Expert Reports
Showing Results 0 of 0
Drug interactions may matter when the effect, safety profile, labeling, dosage recommendations, or expected exposure of a pharmaceutical product is disputed. Relevant materials can include prescribing information, pharmacokinetic data, interaction studies, dosing records, and information concerning other medications taken at the same time. FDA notes that drug-drug interactions can alter systemic exposure and may affect efficacy or increase adverse reactions, which is why interaction assessment forms part of drug development and labeling. Where the case turns principally on pharmacokinetics, pharmacodynamics, or mechanisms of interaction, separate Pharmacology expertise may be appropriate.
Biopharmaceutical matters may involve biological drug products whose development, manufacturing, characterization, or comparability raises pharmaceutical questions. Biosimilars present a more specialized subset because they are evaluated against an FDA-approved reference biological product. FDA defines a biosimilar as a biologic that is highly similar to its reference product and has no clinically meaningful differences in safety, purity, and potency. Biological products can also present more complex manufacturing and characterization issues than many conventional small-molecule drugs. If the dispute is primarily about biotechnology processes, living production systems, or broader biotechnology science rather than the pharmaceutical product itself, separate Biotechnology expertise may be more appropriate.
Useful records may include batch production records, manufacturing instructions, raw-material specifications, equipment and process records, validation documentation, in-process testing, finished-product testing, deviation reports, stability data, and quality-control documentation. FDA's current good manufacturing practice framework addresses the methods, facilities, and controls used in manufacturing, processing, and packing drug products. A suitably qualified pharmaceutical expert may compare the available manufacturing records with the technical question being litigated and assess whether the evidence supports allegations involving product consistency, process deviations, composition, or manufacturing performance.
Pharmaceutical, +4
Pharmaceutical
Biotechnology, +4
Biotechnology
Prepares clear, well-supported expert reports outlining methodology, analysis, findings, and opinions.
Provide Deposition Testimony
Explains findings and opinions under oath and responds to questioning during deposition testimony.
Testify in Court
Presents specialized findings and opinions clearly to judges, juries, arbitrators, or other decision-makers.
Development records can become significant when the dispute concerns formulation choices, product testing, dose selection, stability, manufacturing scale-up, labeling support, or how information about a pharmaceutical product developed over time. Relevant materials may span laboratory research, preclinical work, clinical studies, regulatory submissions, and post-market information. FDA describes drug development as a sequence that includes discovery and development, preclinical research, clinical research, regulatory review, and post-market safety monitoring. The appropriate expert depends on which stage and technical question are actually disputed.
A pharmaceutical expert may address product-specific information such as dosage form, strength, labeling, formulation, prescribing information, or known product characteristics when those facts are relevant to an alleged overdose. The expert should not automatically be treated as the appropriate professional to determine toxic dose, physiological effect, impairment, or medical causation. Those questions may require Toxicology, Pharmacology, or clinical medical expertise depending on the evidence and opinions at issue. For prescription drug and biological-product labeling subject to 21 C.F.R. § 201.57, FDA regulations separately address Overdosage and Clinical Pharmacology, including pharmacokinetic and pharmacodynamic information.
Pharmaceutical, +4
Pharmaceutical
Food And Drug Administration (FDA), +4
Pharmaceutical
